NCT02744053View on ClinicalTrials.gov

DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

November 7, 2016

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Estrogen Receptor NegativeHER2/Neu NegativeProgesterone Receptor NegativeTriple-Negative Breast Carcinoma
Interventions
PROCEDURE

Dynamic Contrast-Enhanced Magnetic Resonance Imaging

Undergo DCE-MRI

OTHER

Laboratory Biomarker Analysis

Correlative studies

RADIATION

Scintimammography

Undergo MBI

DRUG

Technetium Tc-99m Sestamibi

Given via injection

Trial Locations (6)

77024

Memorial Hermann Memorial City Medical Center, Houston

77030

M D Anderson Cancer Center, Houston

77058

MD Anderson League City, Nassau Bay

77094

MD Anderson in Katy, Houston

77384

MD Anderson in The Woodlands, The Woodlands

77478

MD Anderson in Sugar Land, Sugar Land

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER